Not logged in
  • Log in
    Membership (40163+) Group hosting [?] Wiki
    Franklin Award

    About bioinformatics
    Bioinformatics training
    Bioinformatics jobs

    All information groups
    Online databases Online analysis tools Online education tools More tools

    All software groups
    FTP repository
    SVN & CVS repositories [?]
    Mailing lists

    News & Commentary
  • Submit
  • Archives
  • Subscribe

  • Jobs Forum
    (Career Center)
  • Submit
  • Archives
  • Subscribe
  • News & Commentary - Message forums

    Open Access: Ars Technica: Myriad, fresh off Supreme Court loss, keeps on suing over gene patents
    Submitted by J.W. Bizzaro; posted on Saturday, July 13, 2013



    But while health advocates expected Myriad's dominance of testing in this area to be over, Myriad and its lawyers see things quite differently. The Supreme Court's allowance of patents on another type of genetic material – cDNA – means that Myriad can still stop competitors from offering specific types of tests relating to the genes. It has other, differently worded patents that the competing tests are still infringing, according to Myriad lawyers.

    The company is still flush with genetic patents it says remain valid. It originally owned 520 valid patent claims, and the Supreme Court decision merely "reduc[ed] the overall patent estate to 24 patents and 515 patent claims," lawyers wrote in documents filed Tuesday and Wednesday.


    Expanded view | Monitor forum | Save place

    Start a new thread:
    You have to be logged in to post a reply.


    Copyright © 2018 · Scilico, LLC